FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3100338904> ?p ?o ?g. }

• W3100338904 endingPage "A574" @default.
• W3100338904 startingPage "A574" @default.
• W3100338904 abstract "Background Cytotoxic (CD8 + ) T-cells are required for tumor eradication and durable anti-tumor immunity. 1 The induction of tumor-reactive CD8 + T-cells is predominately attributed to a subset of dendritic cells (DC) called Batf3-driven DC1, given their robust ability to cross-present antigens for T-cell priming and their role in effector T-cell recruitment. 2–4 Presence of the DC1 signature in tumors correlates with improved survival and response to immunotherapies. 5–7 Yet, most tumors with a DC1 infiltrate still progress, suggesting that while DC1 can initiate tumor-reactive CD8 + T-cell responses, they are unable to sustain them. Therefore, there is a critical need to identify and engage additional stimulatory DC subsets to strengthen anti-tumor immunity and boost immunotherapy responses. Methods To identify DC subsets that drive poly-functional CD8 + T-cell responses, we compared the DC infiltrate of a spontaneously regressing tumor with a progressing tumor. Multicolor flow immunophenotyping and single-cell RNA-sequencing were used to profile the DC compartment of both tumors. IFNγ-ELISpot was performed on splenocytes to assess for systemic tumor-reactive T-cell responses. Sorted DC subsets from tumors were co-cultured with TCR-transgenic T-cells ex vivo to evaluate their stimulatory capacity. Cross-dressing (in vivo/ex vivo) was assayed by staining for transfer of tumor-derived H-2 b MHC complexes to Balb/c DC, which express the H-2 d haplotype. Protective systemic immunity was assayed via contralateral flank tumor outgrowth experiments. Results Regressor tumors were infiltrated with more cross-presenting DC1 than progressor tumors. However, tumor-reactive CD8 + T-cell responses and tumor control were preserved in Batf3 -/- mice lacking DC1, indicating that anti-tumor immune responses could be induced independent of DC1. Through functional assays, we established that anti-tumor immunity against regressor tumors required CD11c + DC and cGAS/STING-independent type-I-interferon-sensing. Single-cell RNA-sequencing of the immune infiltrate of regressor tumors revealed a novel CD11b + DC subset expressing an interferon-stimulated gene signature (ISG + DC). Flow studies demonstrated that ISG + DC were more enriched in regressor tumors than progressor tumors. We showed that ISG + DC could activate CD8 + T-cells by cross-dressing with tumor-derived peptide-MHC complexes, thereby bypassing the requirement for cross-presentation to initiate CD8 + T-cell-driven immunity. ISG + DC highly expressed cytosolic dsRNA sensors (RIG-I/MDA5) and could be therapeutically harnessed by exogenous addition of a dsRNA analog to drive protective CD8 + T-cell responses in DC1-deficient mice. Conclusions The DC infiltrate in tumors can dictate the strength of anti-tumor immunity. Harnessing multiple stimulatory DC subsets, such as cross-presenting DC1 and cross-dressing ISG + DC, provides a therapeutic opportunity to enhance anti-tumor immunity and increase immunotherapy responses. References Fridman WH, et al. The immune contexture in human tumours: impact on clinical outcome. Nature Reviews Cancer 2012;12(4): p. 298–306. Hildner K, et al. Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in cytotoxic T cell immunity. Science 2008;322(5904):p. 1097–100. Spranger S, et al. Tumor-Residing Batf3 dendritic cells are required for effector T cell trafficking and adoptive T cell therapy. Cancer Cell 2017;31(5):p. 711–723.e4. Roberts, EW, et al., Critical role for CD103(+)/CD141(+) dendritic cells bearing CCR7 for tumor antigen trafficking and priming of T cell immunity in melanoma. Cancer Cell 2016;30(2): p. 324–336. Broz ML, et al. Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. Cancer Cell 2014;26(5): p. 638–52. Salmon H., et al., Expansion and activation of CD103(+) dendritic cell progenitors at the tumor site enhances tumor responses to therapeutic PD-L1 and BRAF inhibition. Immunity , 2016. 44(4): p. 924–38. Sánchez-Paulete AR, et al., Cancer immunotherapy with immunomodulatory anti-CD137 and Anti-PD-1 monoclonal antibodies requires BATF3-dependent dendritic cells. Cancer Discov , 2016;6(1):p. 71–9." @default.
• W3100338904 created "2020-11-23" @default.
• W3100338904 creator A5013574777 @default.
• W3100338904 creator A5058829655 @default.
• W3100338904 creator A5058982168 @default.
• W3100338904 creator A5087403072 @default.
• W3100338904 date "2020-11-01" @default.
• W3100338904 modified "2023-09-25" @default.
• W3100338904 title "538 Harnessing cross-dressing dendritic cells to strengthen anti-tumor immunity" @default.
• W3100338904 doi "https://doi.org/10.1136/jitc-2020-sitc2020.0538" @default.
• W3100338904 hasPublicationYear "2020" @default.
• W3100338904 type Work @default.
• W3100338904 sameAs 3100338904 @default.
• W3100338904 citedByCount "0" @default.
• W3100338904 crossrefType "journal-article" @default.
• W3100338904 hasAuthorship W3100338904A5013574777 @default.
• W3100338904 hasAuthorship W3100338904A5058829655 @default.
• W3100338904 hasAuthorship W3100338904A5058982168 @default.
• W3100338904 hasAuthorship W3100338904A5087403072 @default.
• W3100338904 hasConcept C100701293 @default.
• W3100338904 hasConcept C147483822 @default.
• W3100338904 hasConcept C150903083 @default.
• W3100338904 hasConcept C154317977 @default.
• W3100338904 hasConcept C167672396 @default.
• W3100338904 hasConcept C202751555 @default.
• W3100338904 hasConcept C203014093 @default.
• W3100338904 hasConcept C207001950 @default.
• W3100338904 hasConcept C26291073 @default.
• W3100338904 hasConcept C2776090121 @default.
• W3100338904 hasConcept C2777701055 @default.
• W3100338904 hasConcept C2778170410 @default.
• W3100338904 hasConcept C2779053233 @default.
• W3100338904 hasConcept C502942594 @default.
• W3100338904 hasConcept C55493867 @default.
• W3100338904 hasConcept C59822182 @default.
• W3100338904 hasConcept C71924100 @default.
• W3100338904 hasConcept C81444415 @default.
• W3100338904 hasConcept C86803240 @default.
• W3100338904 hasConcept C8891405 @default.
• W3100338904 hasConcept C90375314 @default.
• W3100338904 hasConceptScore W3100338904C100701293 @default.
• W3100338904 hasConceptScore W3100338904C147483822 @default.
• W3100338904 hasConceptScore W3100338904C150903083 @default.
• W3100338904 hasConceptScore W3100338904C154317977 @default.
• W3100338904 hasConceptScore W3100338904C167672396 @default.
• W3100338904 hasConceptScore W3100338904C202751555 @default.
• W3100338904 hasConceptScore W3100338904C203014093 @default.
• W3100338904 hasConceptScore W3100338904C207001950 @default.
• W3100338904 hasConceptScore W3100338904C26291073 @default.
• W3100338904 hasConceptScore W3100338904C2776090121 @default.
• W3100338904 hasConceptScore W3100338904C2777701055 @default.
• W3100338904 hasConceptScore W3100338904C2778170410 @default.
• W3100338904 hasConceptScore W3100338904C2779053233 @default.
• W3100338904 hasConceptScore W3100338904C502942594 @default.
• W3100338904 hasConceptScore W3100338904C55493867 @default.
• W3100338904 hasConceptScore W3100338904C59822182 @default.
• W3100338904 hasConceptScore W3100338904C71924100 @default.
• W3100338904 hasConceptScore W3100338904C81444415 @default.
• W3100338904 hasConceptScore W3100338904C86803240 @default.
• W3100338904 hasConceptScore W3100338904C8891405 @default.
• W3100338904 hasConceptScore W3100338904C90375314 @default.
• W3100338904 hasIssue "Suppl 3" @default.
• W3100338904 hasLocation W31003389041 @default.
• W3100338904 hasOpenAccess W3100338904 @default.
• W3100338904 hasPrimaryLocation W31003389041 @default.
• W3100338904 hasRelatedWork W1591368579 @default.
• W3100338904 hasRelatedWork W1918925546 @default.
• W3100338904 hasRelatedWork W2008057646 @default.
• W3100338904 hasRelatedWork W2055715607 @default.
• W3100338904 hasRelatedWork W2104085064 @default.
• W3100338904 hasRelatedWork W2174267452 @default.
• W3100338904 hasRelatedWork W3100338904 @default.
• W3100338904 hasRelatedWork W3174314443 @default.
• W3100338904 hasRelatedWork W4306732349 @default.
• W3100338904 hasRelatedWork W2051367948 @default.
• W3100338904 hasVolume "8" @default.
• W3100338904 isParatext "false" @default.
• W3100338904 isRetracted "false" @default.
• W3100338904 magId "3100338904" @default.
• W3100338904 workType "article" @default.